{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:23:34Z","timestamp":1755797014485,"version":"3.44.0"},"reference-count":24,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>There is some evidence that mastocytosis patients are at increased risk of skin cancer. This study aimed to assess the risk of malignant melanoma (MM), melanoma in situ (Mis), and basal cell carcinoma (BCC). A dataset was generated by individual-level record linkages between Swedish population registers including the National Patient Register (NPR), the Swedish Cancer Register (SCR), and the Population Register (PR). Adult patients with a mastocytosis diagnosis between 2001 and 2018 were identified in the SCR and NPR. For each case, 5 mastocytosis-free comparators matched on age, sex, and county of residence were randomly chosen from the PR. Records of skin cancer were identified in the SCR and NPR. In total, the study encompassed 2,040 mastocytosis patients of whom 63 had a record of MM\/Mis and 168 a record of BCC. Compared with comparators, the risk of MM\/Mis was more than twofold higher (OR 2.39, 95% CI 1.8\u20133.2). Risk estimates for BCC were also elevated (OR 1.77, 95% CI 1.49\u20132.14). When assessing the timing of skin cancers, a substantial portion were diagnosed near index date. Taken together, in the present study these findings of increased risk of MM\/Mis and BCC in mastocytosis patients may reflect an influence of detection bias.<\/jats:p>","DOI":"10.2340\/actadv.v105.43052","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:54:18Z","timestamp":1755518058000},"page":"adv43052","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias \u2013 A Registry-based Study (Sweden)"],"prefix":"10.2340","volume":"105","author":[{"given":"Anna","family":"Bergstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"121464","doi-asserted-by":"crossref","unstructured":"Dahlin JS, Maurer M, Metcalfe DD, Pejler G, Sagi-Eisenberg R, Nilsson G. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy 2022; 77: 83\u201399.","DOI":"10.1111\/all.14881"},{"key":"121465","doi-asserted-by":"crossref","unstructured":"Maurer M, K\u00f6berle M, Metz M, Biedermann T. Mast cells: promoters of health and modulators of disease. J Allergy Clin Immunol 2019; 144: S1\u20133.","DOI":"10.1016\/j.jaci.2019.01.048"},{"key":"121466","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere 2021; 5: e646.","DOI":"10.1097\/HS9.0000000000000646"},{"key":"121467","doi-asserted-by":"crossref","unstructured":"Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35\u201345.","DOI":"10.1016\/j.jaci.2015.08.034"},{"key":"121468","doi-asserted-by":"crossref","unstructured":"Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, et al. Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis. J Invest Dermatol 2021; 141: 1719\u20131727.","DOI":"10.1016\/j.jid.2020.12.030"},{"key":"121469","doi-asserted-by":"crossref","unstructured":"Bergstr\u00f6m A, H\u00e4gglund H, Berglund A, Nilsson G, Lambe M. Epidemiology of mastocytosis: a population-based study (Sweden). Acta Oncol 2024; 63: 44\u201350.","DOI":"10.2340\/1651-226X.2024.31406"},{"key":"121470","doi-asserted-by":"crossref","unstructured":"G\u00fclen T, Akin C. Anaphylaxis and mast cell disorders. Immunol Allergy Clin North Am 2022; 42: 45\u201363.","DOI":"10.1016\/j.iac.2021.09.007"},{"key":"121471","doi-asserted-by":"crossref","unstructured":"Donker ML, Bakker NA, Jaspers WJM, Verhage AH. Two patients with osteoporosis: initial presentation of systemic mastocytosis. J Bone Miner Metab 2008; 26: 199\u2013202.","DOI":"10.1007\/s00774-007-0800-x"},{"key":"121472","doi-asserted-by":"crossref","unstructured":"Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord 2016; 17: 419\u2013431.","DOI":"10.1007\/s11154-016-9362-3"},{"key":"121473","doi-asserted-by":"crossref","unstructured":"Broesby-Olsen S, Farkas DK, Vestergaard H, Hermann AP, M\u00f8ller MB, Mortz CG, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol 2016; 91: 1069\u20131075.","DOI":"10.1002\/ajh.24490"},{"key":"121474","doi-asserted-by":"crossref","unstructured":"Kibsgaard L, Deleuran M, Flohr C, Langan S, Braae Olesen A, Vestergaard C. How \u201cbenign\u201d is cutaneous mastocytosis? A Danish registry-based matched cohort study. Int J Womens Dermatol 2020; 6: 294\u2013300.","DOI":"10.1016\/j.ijwd.2020.05.013"},{"key":"121475","doi-asserted-by":"crossref","unstructured":"Todd P, Garioch J, Seywright M, Rademaker M, Thomson J. Malignant melanoma and systemic mastocytosis \u2013 a possible association? Clin Exp Dermatol 1991; 16: 455\u2013457.","DOI":"10.1111\/j.1365-2230.1991.tb01235.x"},{"key":"121476","doi-asserted-by":"crossref","unstructured":"Kowalzic L, Eickenscheidt L, Seidel C, Kribus S, Ziegler H, Komar M. Telangiectasia macularis eruptiva perstans, a form of cutaneous mastocytosis, associated with malignant melanoma. J Dtsch Dermatol Ges 2009; 7: 360\u2013362.","DOI":"10.1111\/j.1610-0387.2008.06941.x"},{"key":"121477","doi-asserted-by":"crossref","unstructured":"H\u00e4gglund H, Sander B, G\u00fclen T, Lindel\u00f6f B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol 2014; 94: 583\u2013584.","DOI":"10.2340\/00015555-1788"},{"key":"121478","doi-asserted-by":"crossref","unstructured":"Donati P, Paolino G, Donati M, Panetta C. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma: coincidence or a linkage in the pathogenesis? J Dermatol Case Rep 2014; 8: 70\u201374.","DOI":"10.3315\/jdcr.2014.1179"},{"key":"121479","doi-asserted-by":"crossref","unstructured":"Ruini C, Hartmann D, Flaig MJ, von Braunm\u00fchl T, Berking C. [Aggressive malignant melanoma in a patient with urticaria pigmentosa]. Hautarzt Z Dermatol Venerol Verwandte Geb 2018; 69: 45\u201348.","DOI":"10.1007\/s00105-018-4220-8"},{"key":"121480","doi-asserted-by":"crossref","unstructured":"Capo A, Goteri G, Mozzicafreddo G, Serresi S, Giacchetti A. Melanoma and mastocytosis: is really only a coincidence? Clin Exp Dermatol 2019; 44: 76\u201377.","DOI":"10.1111\/ced.13717"},{"key":"121481","doi-asserted-by":"crossref","unstructured":"Akdogan N, Elcin G, Gokoz O. The co-existence of cutaneous melanoma and urticaria pigmentosa in a patient with Becker\u2019s nevus. J Cosmet Dermatol 2020; 19: 1268\u20131270.","DOI":"10.1111\/jocd.13243"},{"key":"121482","doi-asserted-by":"crossref","unstructured":"Rydberg A, Lehman J, Markovic S, Anderson K. Mastocytosis and melanoma: a case series. Int J Dermatol 2022; 61: 603\u2013606.","DOI":"10.1111\/ijd.15791"},{"key":"121483","unstructured":"Svenska melanomregistret (SweMR) \u2013 kvalitetsregisterrapport, 1990\u20132022. https:\/\/cancercentrum.se\/globalassests\/om-rcc\/sydost\/pdf\/nationell-kvalitetsregisterrapport-hudmelanom-1990-2022.pdf"},{"key":"121484","doi-asserted-by":"crossref","unstructured":"Kappelin J, Green AC, Ingvar \u00c5, Ahnlide I, Nielsen K. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br J Dermatol 2022; 186: 963\u2013969.","DOI":"10.1111\/bjd.20964"},{"key":"121485","doi-asserted-by":"crossref","unstructured":"Vojvodic A, Vlaskovic-Jovicevic T, Vojvodic P, Vojvodic J, Goldust M, Peric-Hajzler Z, et al. Melanoma and mastocytosis. Open Access Maced J Med Sci 2019; 7: 3050\u20133052.","DOI":"10.3889\/oamjms.2019.772"},{"key":"121486","doi-asserted-by":"crossref","unstructured":"Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Ma\u00eetre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26: 22\u201331.","DOI":"10.1111\/j.1468-3083.2012.04520.x"},{"key":"121487","doi-asserted-by":"crossref","unstructured":"Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66: 553\u2013562.","DOI":"10.1016\/j.jaad.2011.04.004"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43052\/51083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43052\/51083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:54:21Z","timestamp":1755518061000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43052","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"type":"electronic","value":"1651-2057"},{"type":"print","value":"0001-5555"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}